A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 6, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing securities to trade at artificially inflated prices. Investors who suffered losses are encouraged to contact the law firm or submit claims by September 28, 2026 to potentially serve as lead plaintiff.

Bernstein Liebhard LLP, an investor rights law firm, has announced investigations into potential breaches of fiduciary duty by directors and officers at AeroVironment, Capricor Therapeutics, and Calix. The firm is seeking to determine whether company leadership fulfilled obligations to shareholders and whether legal remedies may be available. Current shareholders are encouraged to contact the firm for consultation.

Bernstein Liebhard LLP has filed securities class action lawsuits against Avis Budget Group for allegedly orchestrating a market manipulation scheme involving short squeezes, and is investigating potential breaches of fiduciary duty at Capricor Therapeutics and Calix. Investors who suffered losses during the specified periods are encouraged to participate in the class actions.

Bernstein Liebhard LLP has filed securities class action lawsuits against Wise Group plc, Capricor Therapeutics, Inc., and is investigating Calix, Inc. for alleged materially false and misleading statements regarding business operations and financial stability. Investors who purchased securities during specified periods are encouraged to contact the firm to discuss their rights and potential recovery.

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Gartner, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation targets shareholders who purchased shares before February 24, 2025.

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Calix, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation focuses on shareholders who purchased shares before January 28, 2026.

Class action lawsuits have been filed against AeroVironment, Calix, Zoetis, and Lucid Group, alleging that company executives made materially false statements and failed to disclose material adverse facts about their businesses. The lawsuits cover various issues including understated competition, supply chain problems, declining product adoption, and manufacturing disruptions. Lead plaintiff deadlines range from July 27-28, 2026.

A class action lawsuit has been filed against Calix, Inc. for allegedly making materially false statements about gross margins during Q1 2026. The company failed to disclose that its margins benefited from advanced memory component purchasing and that it faced significant margin pressure as this supply dwindled. The stock fell 13.98% on April 22, 2026 following the earnings announcement. The deadline to file a lead plaintiff motion is July 27, 2026.

Rosen Law Firm is notifying investors in Calix, Inc., Embecta Corp., and Lucid Group, Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding financial performance and business operations during specified class periods.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Embecta Corp., where investors who purchased stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The lawsuit alleges that Embecta made false statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance. The lead plaintiff deadline is August 17, 2026. Similar class actions are also mentioned for Calix, Inc. and Lucid Group, Inc.

A class action lawsuit has been filed against Calix, Inc. alleging that the company failed to disclose that its first quarter margins benefited from advanced purchasing of memory components, that supplies were dwindling, and that the company faced negative margin pressure from rising memory component costs. Investors who purchased Calix securities between January 28, 2026 and April 21, 2026 are encouraged to join the case, with a lead plaintiff deadline of July 27, 2026.